1
|
Liu C, Hu Y, Lin J, Fu H, Lim LY, Yuan Z. Targeting strategies for drug delivery to the kidney: From renal glomeruli to tubules. Med Res Rev 2018; 39:561-578. [DOI: 10.1002/med.21532] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2018] [Revised: 07/10/2018] [Accepted: 07/18/2018] [Indexed: 12/22/2022]
Affiliation(s)
- Chun‐Ping Liu
- Department of PharmacyCollege of Veterinary Medicine, Sichuan Agricultural UniversityChengdu China
- Key Laboratory of Animal Disease and Human Health of Sichuan ProvinceChengdu China
| | - You Hu
- Department of PharmacyCollege of Veterinary Medicine, Sichuan Agricultural UniversityChengdu China
- Key Laboratory of Animal Disease and Human Health of Sichuan ProvinceChengdu China
| | - Ju‐Chun Lin
- Department of PharmacyCollege of Veterinary Medicine, Sichuan Agricultural UniversityChengdu China
- Key Laboratory of Animal Disease and Human Health of Sichuan ProvinceChengdu China
| | - Hua‐Lin Fu
- Department of PharmacyCollege of Veterinary Medicine, Sichuan Agricultural UniversityChengdu China
- Key Laboratory of Animal Disease and Human Health of Sichuan ProvinceChengdu China
| | - Lee Yong Lim
- Pharmacy, Centre for Optimization of Medicines, School of Allied Health, The University of Western AustraliaCrawley Australia
| | - Zhi‐Xiang Yuan
- Department of PharmacyCollege of Veterinary Medicine, Sichuan Agricultural UniversityChengdu China
- Key Laboratory of Animal Disease and Human Health of Sichuan ProvinceChengdu China
| |
Collapse
|
2
|
Abstract
Treatment and management of kidney disease currently presents an enormous global burden, and the application of nanotechnology principles to renal disease therapy, although still at an early stage, has profound transformative potential. The increasing translation of nanomedicines to the clinic, alongside research efforts in tissue regeneration and organ-on-a-chip investigations, are likely to provide novel solutions to treat kidney diseases. Our understanding of renal anatomy and of how the biological and physico-chemical properties of nanomedicines (the combination of a nanocarrier and a drug) influence their interactions with renal tissues has improved dramatically. Tailoring of nanomedicines in terms of kidney retention and binding to key membranes and cell populations associated with renal diseases is now possible and greatly enhances their localization, tolerability, and efficacy. This Review outlines nanomedicine characteristics central to improved targeting of renal cells and highlights the prospects, challenges, and opportunities of nanotechnology-mediated therapies for renal diseases.
Collapse
|
3
|
Castellanos-Gonzalez A, Perry N, Nava S, White AC. Preassembled Single-Stranded RNA-Argonaute Complexes: A Novel Method to Silence Genes in Cryptosporidium. J Infect Dis 2016; 213:1307-14. [PMID: 26656125 PMCID: PMC4799669 DOI: 10.1093/infdis/jiv588] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2015] [Accepted: 11/27/2015] [Indexed: 11/14/2022] Open
Abstract
Cryptosporidiosis is a common cause of diarrhea morbidity and mortality worldwide. Research progress on this infection has been slowed by lack of methods to genetically manipulate Cryptosporidium parasites. Small interfering RNA (siRNA) is widely used to study gene function, but Cryptosporidium species lack the enzymes necessary to process siRNA. By preassembling complexes with the human enzyme Argonaute 2 (hAgo2) and Cryptosporidium single-stranded RNA (ssRNA), we induced specific slicing in Cryptosporidium RNA targets. We demonstrated the reduction in expression of target genes at the mRNA and protein levels by transfecting live parasites with ssRNA-hAgo2 complexes. Furthermore we used this method to confirm the role of selected molecules during host cell invasion. This novel method provides a novel means of silencing Cryptosporidium genes to study their role in host-parasite interactions and as potential targets for chemotherapy.
Collapse
Affiliation(s)
| | - Nicolas Perry
- Infectious Disease Division, Department of Internal Medicine, University of Texas Medical Branch, Galveston
| | - Samantha Nava
- Infectious Disease Division, Department of Internal Medicine, University of Texas Medical Branch, Galveston
| | - A Clinton White
- Infectious Disease Division, Department of Internal Medicine, University of Texas Medical Branch, Galveston
| |
Collapse
|
4
|
Lal MA, Young KW, Andag U. Targeting the podocyte to treat glomerular kidney disease. Drug Discov Today 2015; 20:1228-34. [DOI: 10.1016/j.drudis.2015.06.003] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2015] [Revised: 05/28/2015] [Accepted: 06/11/2015] [Indexed: 12/19/2022]
|
5
|
Visweswaran GRR, Gholizadeh S, Ruiters MHJ, Molema G, Kok RJ, Kamps JAAM. Targeting Rapamycin to Podocytes Using a Vascular Cell Adhesion Molecule-1 (VCAM-1)-Harnessed SAINT-Based Lipid Carrier System. PLoS One 2015; 10:e0138870. [PMID: 26407295 PMCID: PMC4583306 DOI: 10.1371/journal.pone.0138870] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2014] [Accepted: 09/04/2015] [Indexed: 11/24/2022] Open
Abstract
Together with mesangial cells, glomerular endothelial cells and the basement membrane, podocytes constitute the glomerular filtration barrier (GFB) of the kidney. Podocytes play a pivotal role in the progression of various kidney-related diseases such as glomerular sclerosis and glomerulonephritis that finally lead to chronic end-stage renal disease. During podocytopathies, the slit-diaphragm connecting the adjacent podocytes are detached leading to severe loss of proteins in the urine. The pathophysiology of podocytopathies makes podocytes a potential and challenging target for nanomedicine development, though there is a lack of known molecular targets for cell selective drug delivery. To identify VCAM-1 as a cell-surface receptor that is suitable for binding and internalization of nanomedicine carrier systems by podocytes, we investigated its expression in the immortalized podocyte cell lines AB8/13 and MPC-5, and in primary podocytes. Gene and protein expression analyses revealed that VCAM-1 expression is increased by podocytes upon TNFα-activation for up to 24 h. This was paralleled by anti-VCAM-1 antibody binding to the TNFα-activated cells, which can be employed as a ligand to facilitate the uptake of nanocarriers under inflammatory conditions. Hence, we next explored the possibilities of using VCAM-1 as a cell-surface receptor to deliver the potent immunosuppressant rapamycin to TNFα-activated podocytes using the lipid-based nanocarrier system Saint-O-Somes. Anti-VCAM-1-rapamycin-SAINT-O-Somes more effectively inhibited the cell migration of AB8/13 cells than free rapamycin and non-targeted rapamycin-SAINT-O-Somes indicating the potential of VCAM-1 targeted drug delivery to podocytes.
Collapse
Affiliation(s)
- Ganesh Ram R. Visweswaran
- Department of Pathology & Medical Biology, Medical Biology Section, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
| | - Shima Gholizadeh
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands
| | - Marcel H. J. Ruiters
- Department of Pathology & Medical Biology, Medical Biology Section, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
| | - Grietje Molema
- Department of Pathology & Medical Biology, Medical Biology Section, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
| | - Robbert J. Kok
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands
| | - Jan. A. A. M. Kamps
- Department of Pathology & Medical Biology, Medical Biology Section, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
- * E-mail:
| |
Collapse
|
6
|
Yanik M, Alzubi J, Lahaye T, Cathomen T, Pingoud A, Wende W. TALE-PvuII fusion proteins--novel tools for gene targeting. PLoS One 2013; 8:e82539. [PMID: 24349308 PMCID: PMC3857828 DOI: 10.1371/journal.pone.0082539] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2013] [Accepted: 11/01/2013] [Indexed: 12/15/2022] Open
Abstract
Zinc finger nucleases (ZFNs) consist of zinc fingers as DNA-binding module and the non-specific DNA-cleavage domain of the restriction endonuclease FokI as DNA-cleavage module. This architecture is also used by TALE nucleases (TALENs), in which the DNA-binding modules of the ZFNs have been replaced by DNA-binding domains based on transcription activator like effector (TALE) proteins. Both TALENs and ZFNs are programmable nucleases which rely on the dimerization of FokI to induce double-strand DNA cleavage at the target site after recognition of the target DNA by the respective DNA-binding module. TALENs seem to have an advantage over ZFNs, as the assembly of TALE proteins is easier than that of ZFNs. Here, we present evidence that variant TALENs can be produced by replacing the catalytic domain of FokI with the restriction endonuclease PvuII. These fusion proteins recognize only the composite recognition site consisting of the target site of the TALE protein and the PvuII recognition sequence (addressed site), but not isolated TALE or PvuII recognition sites (unaddressed sites), even at high excess of protein over DNA and long incubation times. In vitro, their preference for an addressed over an unaddressed site is > 34,000-fold. Moreover, TALE-PvuII fusion proteins are active in cellula with minimal cytotoxicity.
Collapse
Affiliation(s)
- Mert Yanik
- Institute for Biochemistry, Justus-Liebig-University Giessen, Giessen, Germany
| | - Jamal Alzubi
- Institute for Cell and Gene Therapy, University Medical Center Freiburg, Freiburg, Germany
- Center for Chronic Immunodeficiency, University Medical Center Freiburg, Freiburg, Germany
| | - Thomas Lahaye
- ZMBP – General Genetics, University of Tuebingen, Tuebingen, Germany
| | - Toni Cathomen
- Institute for Cell and Gene Therapy, University Medical Center Freiburg, Freiburg, Germany
- Center for Chronic Immunodeficiency, University Medical Center Freiburg, Freiburg, Germany
| | - Alfred Pingoud
- Institute for Biochemistry, Justus-Liebig-University Giessen, Giessen, Germany
| | - Wolfgang Wende
- Institute for Biochemistry, Justus-Liebig-University Giessen, Giessen, Germany
- *
| |
Collapse
|
7
|
Swiatecka-Urban A. Membrane trafficking in podocyte health and disease. Pediatr Nephrol 2013; 28:1723-37. [PMID: 22932996 PMCID: PMC3578983 DOI: 10.1007/s00467-012-2281-y] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/24/2012] [Revised: 07/19/2012] [Accepted: 07/20/2012] [Indexed: 12/21/2022]
Abstract
Podocytes are highly specialized epithelial cells localized in the kidney glomerulus. The distinct cell signaling events and unique cytoskeletal architecture tailor podocytes to withstand changes in hydrostatic pressure during glomerular filtration. Alteration of glomerular filtration leads to kidney disease and frequently manifests with proteinuria. It has been increasingly recognized that cell signaling and cytoskeletal dynamics are coupled more tightly to membrane trafficking than previously thought. Membrane trafficking coordinates the cross-talk between protein networks and signaling cascades in a spatially and temporally organized fashion and may be viewed as a communication highway between the cell exterior and interior. Membrane trafficking involves transport of cargo from the plasma membrane to the cell interior (i.e., endocytosis) followed by cargo trafficking to lysosomes for degradation or to the plasma membrane for recycling. Yet, recent studies indicate that the conventional classification does not fully reflect the complex and versatile nature of membrane trafficking. While the increasing complexity of elaborate protein scaffolds and signaling cascades is being recognized in podocytes, the role of membrane trafficking is less well understood. This review will focus on the role of membrane trafficking in podocyte health and disease.
Collapse
|
8
|
El Hindi S, Reiser J. TRPC channel modulation in podocytes-inching toward novel treatments for glomerular disease. Pediatr Nephrol 2011; 26:1057-64. [PMID: 21161284 PMCID: PMC3098353 DOI: 10.1007/s00467-010-1718-4] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/24/2010] [Revised: 10/29/2010] [Accepted: 11/05/2010] [Indexed: 11/08/2022]
Abstract
Glomerular kidney disease is a major healthcare burden and considered to represent a sum of disorders that evade a refined and effective treatment. Excellent biological and genetic studies have defined pathways that go awry in podocytes, which are the regulatory cells of the glomerular filter. The question now is how to define targets for novel improved therapies. In this review, we summarize critical points around targeting the TRPC6 channel in podocytes.
Collapse
Affiliation(s)
- Shafic El Hindi
- Department of Medicine, Division of Nephrology and Hypertension, Leonard Miller School of Medicine, University of Miami, Miami, FL USA
| | - Jochen Reiser
- Department of Medicine, Division of Nephrology and Hypertension, Leonard Miller School of Medicine, University of Miami, Miami, FL USA ,Department of Medicine, Miller School of Medicine, University of Miami, 1580 NW 10th Avenue, Batchelor Bldg, 6th Fl (R-762), Miami, FL 33136 USA
| |
Collapse
|